论文部分内容阅读
目的:评价恩替卡韦治疗慢性乙型重型肝炎的近期临床疗效.方法:研究本院慢性乙型重型肝炎住院患者180例,其中随机对照组(60例)给予常规综合治疗,治疗组分别在综合治疗基础上加用 LAM(60例)或 ETV(60例)抗病毒治疗,共治疗24周.结果:接受恩替卡韦治疗后6个月时,总胆红素和谷丙转氨酶分别由治疗前的399.03±148.90μmol/L 和682.84±191.09U/L 降至38.82±13.61μmol/L 和68.66±20.18U/L,均较拉米夫定组改善更明显(P<0.05);恩替卡韦组的 HBV DNA 转阴率为87.5%,明显高于拉米夫定组的66.8%(P<0.05).病死率分别为6.67%和15%,有显著性差异(P<0.05).结论:应用恩替卡韦治疗慢性乙型重型肝炎在近期临床疗效、肝功能改善和抑制病毒复制方面明显优于拉米夫定.“,”Objective To evaluate the short-term effects of entecavir (ETV) therapy on chronic severe hepatitis B. Methods Total of 180 cases with chronic severe hepatitis B were analyzed, The control group (60 cases) received conventional therapy and the therapy groups were treated with LAM (60 cases) or ETV (60cases) based on the comprehensive therapy. It lasts for 24 weeks.result After six months, the total bilirubin,drop from 399.03 ± 148.90μmol/L to 38.82 ± 13.61μmol/L. The alanine aminotrans-ferase drop from 682.84 ± 191.09U/L to 38.82 ± 13.61μmol/L.The treatment effect of enticavir is much better than LAM(P<0.05). The negative conversion rate of HBV-DNA is 87.5% in the ETV group. It was obviously higher than the LAM group 66.8%(P<0.05).The mortality was 6.67% and 15% respectively.conclusion The enticavir is much better than LAM In recent therapy and the inhibition of viral replication.